The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

207 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-05-01

Study Completion Date

2017-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective observational study of a cohort of children diagnosed with Attention Deficit Hyperactive Disorder (ADHD) and followed with weekly assessments during the first 12 weeks of Methylphenidate (MPH) treatment, and after three years.

The overall aim is to gain knowledge in order to develop guidelines for more individualized treatments with (MPH), obtain a better drug response, and reduce the risk of adverse reactions, in order to improve adherence and long-term outcome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of CES1 Genotype on Metabolism of Methylphenidate

NCT02147535

Carboxylesterase 1 (CES1) Genotype CES1 Activity

COMPLETED PHASE4

Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD

NCT03781752

ADHD Attention Deficit Hyperactivity Disorder

RECRUITING PHASE4

Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)

NCT00862108

Attention Deficit Hyperactivity Disorder

UNKNOWN PHASE4

ERP Based Single-dose Predictions of Stimulants

NCT02695355

Attention Deficit Hyperactivity Disorder

COMPLETED PHASE2

To Explore the Influence of Appetite Reduction and Medication Effect of Methylphenidate in Patients With Attention-deficit/Hyperactivity Disorder(ADHD) Through Pharmacogenetics.

NCT04006548

Methylphenidate Adverse Reaction

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study has three aims:

1. Examine the effect of carboxylesterase 1 (CES1) genotype in children with ADHD on the effectiveness and adverse reactions of treatment with MPH.
2. Study predictors for the short- and long-term outcome in childhood ADHD
3. Examine the long-term outcome with respect to ADHD symptoms, and impairment in daily functioning in the cohort

The specific aims are to:

* Describe the treatment response during the first 12 weeks after initiation of IR-MPH treatment, based on weekly clinician- rated ADHD core symptoms, the rate of normalisation/ borderline normalisation of ADHD core symptoms, adverse reactions, daily and social functioning, and measures of sustained attention.
* Describe the three-year outcome, based on parent rated ADHD core- and behavior symptoms, and level of impairment in daily functioning.
* Provide information about predictors for outcome after 12 weeks: clinical characteristics at entry (sex, age group, global severity of psychiatric disorder, psychiatric comorbidity, subtype of ADHD diagnoses), and predictors for outcome after three years: sex, age group, baseline severity of ADHD- and behavior symptoms, IQ, parental psychiatric disorder, maternal educational level, and time to treatment response.
* Determine the end-dose of IR-MPH after 12 weeks of treatment.
* Systematically sequence the CES1 gene and associate the identified genotypes of this gene with treatment responses, including dosage of IR-MPH

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

ADHD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ADHD patients

Treatment of young ADHD patients with methylphenidate following The Danish guidelines, which are similar to The NICE guidelines: use of an initial low oral dose of MPH and an up-titration period of at least 4 weeks, until no further effect is measured on a standard ADHD rating scale, or the appearance of intolerable ARs, or a maximum dose of 2.1 mg/kg/day.

Methylphenidate

Intervention Type DRUG

Treatment with methylphenidate through dose escalation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methylphenidate

Treatment with methylphenidate through dose escalation

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Medikinet - N06BA04 Motiron - N06BA04

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MPH naïve
* recent ICD-10 diagnosis of hyperkinetic disorder (F90.0-90.9) or attention deficit disorder without hyperactivity (F98.8)
* clinical indication for treatment with IR-MPH

Exclusion Criteria

* mental retardation (ICD-F70.X or IQ \< 70)
* previous treatment with drugs metabolised by carboxylesterase 1 (CES1)
* severe comorbid psychiatric or somatic disease that resulted in contraindication for treatment with MPH
* language barriers
* lack of informed consent.

* Non-caucasian
* Lack of DNA
* Consanguine patients
* Variants with a minor allele frequency (MAF) above 0.05 or not in Hardy-Weinberg equilibrium

Minimum Eligible Age

7 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No